This article explores the current state of knowledge regarding personalized medicine in psychiatry and discusses how the tools might be used to help psychiatrists understand the components of their patients’ unique endophenotypic profiles.
Data from pivotal international phase III clinical trials showed superior efficacy, safety, and convenience for a new wave of direct-acting oral agents. The breakthrough will benefit physicians in all practice settings, including primary care.
The “take home” from this presentation: be cautious with inappropriate use of drugs with or without black box warnings, but maintain a healthy skepticism about some of these warnings. Cases in point: droperidol, antidepressants, clindamycin.
New findings provide powerful evidence that inhibition of inflammation or its downstream effects on mood may open up a host of new approaches to treatment for depression, especially for patients with treatment resistant depression.
There are many rapidly effective treatments for mania in bipolar disorder. However, there are relatively few options for bipolar depression, and none that are rapidly effective—even though bipolar depression constitutes between 20% to 50% of all depressive disorders.
Charles Bowden, MD, clinical professor in the department of psychiatry at the University of Texas Health Science Center, San Antonio, describes the management of patients with bipolar depression who are pregnant.